- Previous Close
39.69 - Open
40.31 - Bid 41.49 x 100
- Ask 41.76 x 900
- Day's Range
39.97 - 41.80 - 52 Week Range
35.95 - 54.44 - Volume
1,262,865 - Avg. Volume
1,028,874 - Market Cap (intraday)
6.073B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-2.67 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.19
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
www.ionispharma.comRecent News: IONS
Performance Overview: IONS
Trailing total returns as of 6/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IONS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IONS
Valuation Measures
Market Cap
5.81B
Enterprise Value
5.05B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.37
Price/Book (mrq)
19.59
Enterprise Value/Revenue
6.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.54%
Return on Assets (ttm)
-8.13%
Return on Equity (ttm)
-98.27%
Revenue (ttm)
776.62M
Net Income Avi to Common (ttm)
-384.77M
Diluted EPS (ttm)
-2.67
Balance Sheet and Cash Flow
Total Cash (mrq)
2.21B
Total Debt/Equity (mrq)
667.43%
Levered Free Cash Flow (ttm)
-156.68M